Sanger Institute-founded PetMedix is working on antibodies for dogs and cats based on an immune system discovery model that will adapt and extend earlier human health research.
PetMedix, a UK-based veterinary medicine producer co-founded by researchers from Wellcome Trust’s Sanger Institute, has received £8m ($10.6m) in a series A round co-led by fund management unit Parkwalk Advisors.
Parkwalk, a subsidiary of commercialisation firm IP Group, co-led the round alongside venture capital firm Digitalis Ventures.
Founded in 2017, PetMedix develops antibody medications for dogs and cats. Its immune system discovery model will extend earlier research conducted for human health with the hope of uncovering therapies specific…
